Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05633446
PHASE1/PHASE2

Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)

Sponsor: Gylden Pharma Ltd

View on ClinicalTrials.gov

Summary

The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.

Official title: A Phase I-II, Blinded, Randomized, Placebo-controlled Study of a T Cell Priming Next-generation Vaccine Against Coronavirus Disease in Healthy Adults

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

110

Start Date

2025-09-01

Completion Date

2026-12-01

Last Updated

2025-02-24

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

PepGNP-COVID19 (One vaccination)

One dose with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI

OTHER

Water for injection (One vaccination)

Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose

BIOLOGICAL

PepGNP-COVID19 (Two vaccinations)

Two vaccinations with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI

OTHER

Water for injection (Two vaccinations)

Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose

Locations (2)

Health Index Multispecialty Clinic, Barangay Toclong 2B

Imus, Cavite, Philippines

Tropical Disease Foundation

Makati City, National Capital Region, Philippines